Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
LAWRENCEVILLE, N.J., May 04, 2018 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2018 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Friday, May 11, 2018. To participate in the call, interested parties may dial 1-888-298-3457 (Toll-Free/North America) or 1-719-325-4917 (International/Toll) and ask for the Celsion Corporation 1st Quarter 2018 Earnings Call (Conference Code: 6550185) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at www.celsion.com.
The call will be archived for replay on Friday, May 11, 2018 and will remain available until Friday, May 25, 2018. The replay can be accessed at 1-888-203-1112 (Toll-Free/USA) or 1-719-457-0820 (International/Toll) using Conference ID: 6550185. An audio replay of the call will also be available on the Company’s website, www.celsion.com, for 90 days after 2:00 p.m. EDT on Friday, May 11, 2018.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor Contact Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 [email protected]
